APP and Alzheimer disease: Monomeric Aβ‐binding peptide RD2, which renders Aβ unable to form oligomer, reversed AD symptoms (cognition, behavior, and Aβ plaque loads) in aged APP/PS1 mice, indicating its potential for therapeutic application (Schemmert et al., 2019).